| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||
Net income (loss) | ||||||
17,529 | -63,951 | -50,024 | -12,937 | -45,269 | -127,828 | |
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||
Accretion and amortization of debt discount and issuance costs | ||||||
185 | 13,331 | 24,890 | - | - | - | |
Accretion and amortization of debt discount and issuance costs | ||||||
- | - | - | 10,121 | 0 | 0 | |
Write-off of debt discount and issuance costs | ||||||
0 | 54,536 | 12,071 | 0 | - | 5,307 | |
Amortization of Debt Issuance Costs and Discounts | ||||||
- | - | - | 0 | 0 | 138 | |
Loss from change in fair value of redeemable warrants | ||||||
0 | 0 | -16,352 | 1,578 | - | - | |
Gain from change in fair value of embedded derivatives | ||||||
0 | 1,600 | 3,800 | -5,400 | - | - | |
Loss from change in fair value of redeemable warrants | ||||||
- | - | - | - | 0 | - | |
Loss (gain) from change in fair value of embedded derivatives | ||||||
- | - | - | - | 0 | 0 | |
Paid-in-kind interest expense | ||||||
0 | 1,886 | 2,966 | 900 | 0 | 0 | |
Stock-based compensation expense | ||||||
5,532 | 4,394 | 2,963 | 2,297 | 2,272 | 2,080 | |
Depreciation and amortization | ||||||
1,913 | 1,838 | 1,973 | 1,783 | 1,451 | 1,899 | |
Write-off of deferred debt financing costs | ||||||
0 | 704 | 0 | - | - | - | |
Deferred income taxes | ||||||
-337 | -235 | -124 | -520 | -379 | 19 | |
Other | ||||||
-138 | 0 | -381 | 0 | -131 | -53 | |
Make-whole applicable premium included in interest expense | ||||||
0 | 10,410 | 4,607 | 0 | 0 | - | |
Changes in operating assets and liabilities: | ||||||
Accounts receivable | ||||||
31,221 | 18,036 | 8,348 | 14,663 | 8,501 | 9,040 | |
Prepaid expenses, deposits and other | ||||||
9,244 | -555 | 3,359 | 1,427 | 2,676 | 1,045 | |
Deferred contract costs | ||||||
968 | 3,722 | 1,075 | - | - | - | |
Accounts payable | ||||||
-10,513 | 2,875 | 1,200 | 4,636 | 2,257 | -91 | |
Accrued compensation, benefits, commissions and other liabilities | ||||||
8,262 | -1,541 | 5,623 | 10,759 | 8,621 | 5,978 | |
Deferred insurance settlement | ||||||
0 | -8,033 | 8,033 | 0 | - | - | |
Deferred revenue | ||||||
39,110 | 28,971 | 14,834 | - | - | - | |
Deferred insurance settlement | ||||||
0 | -8,033 | 8,033 | 0 | 0 | - | |
Accrued litigation settlement | ||||||
- | - | - | -121,411 | 21,411 | 100,000 | |
Deferred revenue | ||||||
- | - | - | 57,031 | 22,255 | 25,745 | |
Net cash provided by operating activities | ||||||
20,386 | 22,382 | 29,163 | -59,609 | 1,573 | 3,215 | |
CASH FLOWS USED IN INVESTING ACTIVITIES: | ||||||
Capital expenditures | ||||||
1,872 | 1,053 | 1,392 | 1,188 | 1,747 | 1,242 | |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
Net proceeds from issuance of Series A Preferred Stock and Common Stock | ||||||
9,110 | 133,000 | 0 | 0 | - | - | |
Principal payments on borrowings | ||||||
2,555 | 145,807 | 41,994 | 15,313 | 432 | 1,271 | |
Make-whole applicable premium related to prepayment of borrowings | ||||||
- | - | - | - | 0 | - | |
Payments for deferred offering and financing costs | ||||||
- | - | - | 0 | 0 | 2,294 | |
Payments of cash dividends on Series A Preferred Stock | ||||||
14,742 | 2,845 | 0 | 0 | - | - | |
Principal payments on capital leases | ||||||
433 | 587 | 776 | 733 | 430 | 173 | |
Make-whole applicable premium related to prepayment of borrowings | ||||||
0 | 10,410 | 4,607 | 0 | - | - | |
Payments for deferred offering and finance costs | ||||||
452 | 10,159 | 12,361 | 560 | 31 | 176 | |
Proceeds from exercise of employee stock options | ||||||
3,335 | 2,034 | 872 | 44 | 51 | 91 | |
Proceeds from capital infusion in reverse recapitalization | ||||||
0 | 0 | 42,414 | 0 | 0 | - | |
Cash paid to settle stock options of former employees | ||||||
0 | 0 | 38 | 0 | 0 | - | |
Net proceeds from borrowings | ||||||
- | - | - | 83,743 | 0 | 869 | |
Proceeds from Issuance of Preferred Stock and Preference Stock | ||||||
- | - | - | 9,907 | 0 | 0 | |
Net cash provided by (used in) financing activities | ||||||
-5,737 | -34,774 | -16,490 | 77,088 | -842 | -2,954 | |
Effect of foreign currency translation changes | ||||||
405 | -1,376 | 509 | -613 | - | - | |
Net change in cash, cash equivalents and restricted cash | ||||||
13,182 | -14,821 | 11,790 | 15,678 | - | - | |
Effect of foreign currency translation changes | ||||||
- | - | - | - | -285 | -294 | |
Net decrease in cash, cash equivalents and restricted cash | ||||||
- | - | - | - | -1,301 | -1,275 | |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||
Cash paid for interest | ||||||
230 | 19,321 | 16,542 | 2,972 | 829 | 711 | |
Cash paid for income taxes | ||||||
2,184 | 1,765 | 1,730 | 1,609 | 907 | 822 | |
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||
Fair value of 292 and 2,897 shares of Common Stock issued for no consideration in 2019 and 2018, respectively | ||||||
1,098 | 20,131 | 0 | 0 | - | - | |
Original issuance discount on Series A Preferred Stock | ||||||
500 | 7,000 | 0 | - | - | - | |
Transaction costs | ||||||
390 | 0 | 0 | - | - | - | |
Issuance of 120 shares of Common Stock regarding consent for Private Placements | ||||||
638 | 0 | 0 | - | - | - | |
Original issuance discount on Series A Preferred Stock | ||||||
- | - | - | 0 | - | - | |
Accrued cash dividends | ||||||
3,889 | 3,521 | 0 | 0 | - | - | |
Accrued PIK dividends | ||||||
1,156 | 1,056 | 0 | 0 | - | - | |
Accretion of discount on Series A Preferred Stock | ||||||
5,848 | 2,373 | 0 | 0 | - | - | |
Issuance of Series A Preferred Stock for PIK dividends | ||||||
4,385 | 846 | 0 | 0 | - | - | |
Adjustment for updated calculation of mandatory trigger event exit fees | ||||||
0 | 3,952 | 9,414 | 9,957 | 0 | 0 | |
Balance at inception of Credit Facility | ||||||
- | - | - | 45,301 | 0 | 0 | |
Adjustment for mandatory consulting fees due to amendment | ||||||
- | - | - | 6,000 | 0 | 0 | |
Increase in principal for debt discount on GP Sponsor loan | ||||||
0 | 167 | 0 | 0 | - | - | |
Purchase of equipment under capital lease obligations | ||||||
206 | 353 | 214 | 868 | 769 | 883 | |
Capital expenditures | ||||||
0 | 0 | 65 | 47 | 26 | 0 | |
Debt discount for amendment fees under Credit Facility | ||||||
0 | 0 | 5,000 | 0 | 0 | - | |
Credit Facility exit fee obligations converted to principal | ||||||
0 | 0 | 50,000 | 0 | 0 | - | |
Conversion of RSI Preferred Stock to Common Stock in connection with the Mergers | ||||||
0 | 0 | 23,621 | 0 | 0 | - | |
Conversion of RSI Preferred Stock to Common Stock in connection with the Mergers | ||||||
0 | 0 | 19,542 | 0 | 0 | - | |
RSI financial advisor for transaction costs | ||||||
0 | 0 | 2,375 | 0 | 0 | - | |
GPIA deferred underwriting fee liability as reduction of capital infusion | ||||||
0 | 0 | 1,509 | 0 | 0 | - | |
Assumption of note payable to GP Sponsor in connection with the Mergers | ||||||
0 | 0 | 1,992 | 0 | 0 | - | |
Acquisition of prepaid expenses in connection with the Mergers | ||||||
0 | 0 | 14 | 0 | 0 | - | |
Deemed dividend for beneficial conversion feature related to RSI Preferred Stock | ||||||
- | - | - | 10,000 | 0 | 0 | |
Issuance of redeemable warrant in connection with the Credit Facility | ||||||
- | - | - | 8,847 | - | - | |
Issuance of redeemable warrant in connection with the Credit Facility | ||||||
- | - | - | - | 0 | 0 | |